Novel polysaccharide adjuvant from the roots of Actinidia eriantha with dual Th1 and Th2 potentiating activity

Vaccine

Volumn 27, Issue 30, 2009, Pages 3984-3991

  Sun, Hong Xiang ^a   Wang, Hui ^a   Xu, Hai shun ^a,b   Ni, Yang ^a,c  

^a BEIJING HOSPITAL   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Actinidia eriantha; Adjuvant; Cellular and humoral; Polysaccharide; Th1 Th2 immune responses

Indexed keywords

ACTINIDIA ERIANTHA POLYSACCHARIDE; ANTIBODY; CONCANAVALIN A; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MESSENGER RNA; OVALBUMIN; POLYSACCHARIDE; QUIL A; SODIUM CHLORIDE; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; VACCINE;

ACTINIDIA ERIANTHA; ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CELL KILLING; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; KIWIFRUIT; MORTALITY; MOUSE; NONHUMAN; PLANT ROOT; PRIORITY JOURNAL; PROPHYLAXIS; SPLEEN CELL; TH1 CELL; TH2 CELL; TOXICITY; UPREGULATION;

ACTINIDIA; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; CELL PROLIFERATION; CYTOKINES; FEMALE; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED ICR; OVALBUMIN; PLANT ROOTS; POLYSACCHARIDES; SPLEEN; TH1 CELLS; TH2 CELLS;

EID: 67349090621     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.04.037     Document Type: Article

References (75)

1. Lima K.M., dos Santos S.A., Rodrigues Jr. J.M., and Silva C.L. Vaccine adjuvant: it makes the difference. Vaccine 22 19 (2004) 2374-2379
2. O'Hagan D.T., Mackichan M.L., and Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 18 3 (2001) 69-85
3. Rock K.L., Hearn A., Chen C.J., and Shi Y. Natural endogenous adjuvants. Springer Semin Immunopathol 26 3 (2005) 231-246
4. Storni T., Kündig T.M., Senti G., and Johansen P. Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev 57 3 (2005) 333-355
5. Freund J., Casals J., and Hosmer E. Sensitization and antibody formation after injection of tubercle bacili and paraffin oil. Proc Soc Exp Biol Med 37 (1937) 509-513
6. Kensil C.R., and Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Exp Opin Invest Drugs 7 9 (1998) 1475-1482
7. Skene C.D., and Sutton P. Saponin-adjuvanted particulate vaccines for clinical use. Methods 40 1 (2006) 53-59
8. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., and Gupta C.K. Adjuvants: a balance between toxicity and adjuvanticity. Vaccine 11 3 (1993) 293-306
9. Kensil C.R., Patel U., Lennick M., and Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 146 2 (1991) 431-437
10. Kensil C.R., Wu J.Y., and Soltysik S. Structural and immunological characterization of the vaccine adjuvant QS-21. Pharm Biotechnol 6 (1995) 525-541
11. Waite D.C., Jacobson E.W., Ennis F.A., Edelman R., White B., Kammer R., et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 19 28/29 (2001) 3957-3967
12. Janeway Jr. C.A. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 13 1 (1992) 11-16
13. Byars N., and Allison A. Immunologic adjuvants: general properties, advantages, and limitations. In: Zola H. (Ed). Laboratory methods in immunology (1990), CRC Press 39-51
14. Allison A.C., and Byars N.E. Immunological adjuvants and their mode of action. Biotechnology 20 (1992) 431-449
15. Pascual D.M., Morales R.D., Gil E.D., Muñoz L.M., López J.E., and Casanueva O.L.J. Adjuvants: present regulatory challenges. Vaccine 24 S2 (2006) S88-S89
16. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 20 S3 (2002) S34-S39
17. + cytotoxic T lymphocyte responses in vivo. J Immunol 152 (1994) 1110-1119
18. Petrovsky N. Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine 24 S2 (2006) S26-S29
19. Schepetkin I.A., and Quinn M.T. Botanical polysaccharides: macrophage immunomodulation and therapeutic potential. Int Immunopharmacol 6 (2006) 317-323
20. Kong X.F., Hu Y.L., Rui R., Wang D.Y., and Li X.R. Effects of Chinese herbal medicinal ingredients on peripheral lymphocyte proliferation and serum antibody titer after vaccination in chicken. Int Immunopharmacol 7 (2004) 975-982
21. Wang D.Y., Hu Y.L., Sun J.L., Kong X.F., Zhang B.K., and Liu J.G. Comparative study on adjuvanticity of compound Chinese herbal medicinal ingredients. Vaccine 23 (2005) 3704-3708
22. Popov S.V., Golovchenko V.V., Ovodova R.G., Smirnov V.V., Khramova D.S., Popova G.Y., et al. Characterisation of the oral adjuvant effect of lemnan, a pectic polysaccharide of Lemna minor L. Vaccine 24 26 (2006) 5413-5419
23. Qiu Y., Hu Y.L., Cui B.A., Zhang H.Y., Kong X.F., Wang D.Y., et al. Immunopotentiating effects of four Chinese herbal polysaccharides administered at vaccination in chickens. Poult Sci 86 (2007) 2530-2535
24. Dong S.F., Chen J.M., Zhang W., Sun S.H., Wang J., Gu J.X., et al. Specific immune response to HBsAg is enhanced by β-glucan oligosaccharide containing an α-(1→3)-linked bond and biased towards M2/Th2. Int Immunopharmacol 7 6 (2007) 725-733
25. Lu Y., Wang D.Y., Hu Y.L., Huang X.Y., and Wang J.M. Sulfated modification of epimedium polysaccharide and effects of the modifiers on cellular infectivity of IBDV. Carbohydr Polym 2 (2008) 180-186
26. Huang X.Y., Hu Y.L., Zhao X.N., Lu Y., Wang J.M., Zhang F., et al. Sulfated modification can enhance the adjuvanticity activity of Astragalus polysaccharide for ND vaccine. Carbohydr Polym 2 (2008) 303-308
27. Sun Y.X., and Liu J.C. Adjuvant effect of water-soluble polysaccharide (PAP) from the mycelium of Polyporus albicans on the immune responses to ovalbumin in mice. Vaccine 26 31 (2008) 3932-3936
28. da Silva B.P., de Medeiros Silva G., and Parente J.P. Chemical properties and adjuvant activity of a galactoglucomannan from Acrocomia aculeata. Carbohydr Polym 75 3 (2009) 380-384
29. Guo Z.H., Hu Y.L., Wang D.Y., Ma X., Zhao X.N., Zhao B.K., et al. Sulfated modification can enhance the adjuvanticity of lentinan and improve the immune effect of ND vaccine. Vaccine 27 5 (2009) 660-665
30. Nishiyama I., Fukuda T., and Oota T. Genotypic differences in chlorophyll, lutein, and β-carotene. J Agric Food Chem 53 (2005) 6403-6407
31. Zhao Y.P., Wang X.Y., Wang Z.C., Lu Y., Fu C.X., and Chen S.Y. Essential oil of Actinidia macrosperma, a catnip response kiwi endemic to China. J Zhejiang Univ Sci B 7 9 (2006) 708-712
32. Jiangsu New Medical College. Dictionary of Chinese Materia Medica (1977), Shanghai People's Press, Shanghai p. 440
33. Lin S.Q., Yu P., Zhu S.M., Wu X.C., and Yu B.S. Preliminary study on anticancer effect and affecting mouse immune function of crude extracts from the Actinintia eriantha Benth root. J Fujian Normal Univ (Nat Sci Ed) 3 2 (1987) 108-110
34. Xu HS, Wu YW, Sun HX, Yao L. Antitumor and immunomodulatory activity of polysaccharide from the roots of Actinidia eriantha. J Ethnopharmacol; submitted for publication.
35. Larsen S.T., and Nielsen G.D. The adjuvant effect of di-(2-ethylhexyl) phthalate is mediated through a PPARα-independent mechanism. Toxicol Lett 170 3 (2007) 223-228
36. Sun H.X., Xie Yong, and Ye Y.P. Advances in saponin-based adjuvants. Vaccine 27 12 (2009) 1787-1796
37. Xie Y., Ye Y.P., Sun H.X., and Li D. Contribution of the glycidic moieties to the haemolytic and adjuvant activity of platycodigenin-type saponins from the root of Platycodon grandiflorum. Vaccine 26 27 (2008) 3450-3458
38. Xie Y., Sun H.X., and Duo L. Platycodin D is a potent adjuvant of specific cellular and humoral immune responses against recombinant hepatitis B antigen. Vaccine 27 5 (2009) 757-764
39. Dubois M., Gilles K.A., Hamilton J.K., Rebers P.A., and Smith F. Colorimetric method for determination of sugars and related substances. Anal Chem 28 (1956) 350-356
40. Bitter T., and Muir H.M. A modified uronic acid carbazole reaction. Anal Biochem 4 (1962) 330-334
41. Mawhinney T.P., Feather M.S., Barbero G.J., and Martinez J.R. The rapid, quantitative determination of neutral sugars (as aldononitrile acetates) and amino sugars (as O-methyloxime acetates) in glycoproteins by gas-liquid chromatography. Anal Biochem 101 (1980) 112-117
42. Sun H.X., Ye Y.P., Pan H.J., and Pan Y.J. Adjuvant effect of Panax notoginseng saponins on the immune responses to ovalbumin in mice. Vaccine 22 (2004) 3882-3889
43. Tu J., Sun H.X., and Ye Y.P. Immunomodulatory and antitumor activity of triterpenoid fractions from the rhizomes of Astilbe chinensis. J Ethnopharmacol 119 2 (2008) 266-271
44. Barr T.A., Carlring J., and Heath A.W. Co-stimulatory agonists as immunological adjuvants. Vaccine 24 (2006) 3399-3407
45. Marciani D.J. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 8 (2003) 934-943
46. Edelman R. Vaccine adjuvants. Rev Infect Dis 2 3 (1980) 370-383
47. Aguilar J.C., and Rodríguez E.G. Vaccine adjuvants revisited. Vaccine 25 (2007) 3752-3762
48. Sun H.X. Adjuvant effect of Achyranthes bidentata saponins on specific antibody and cellular response to ovalbumin in mice. Vaccine 24 17 (2006) 3432-3439
49. Yang Z.G., Sun H.X., and Fang W.H. Haemolytic activities and adjuvant effect of Astragalus membranaceus saponins on the immune responses to ovalbumin in mice. Vaccine 23 44 (2005) 5196-5203
50. Sun H.X. Haemolytic activities and adjuvant effect of Bupleurum chinense saponins on the immune responses to ovalbumin in mice. Vaccine 24 9 (2006) 1324-1331
51. Sun H.X., and Pan H.J. Immunological adjuvant effect of Glycyrrhiza uralensis saponins on the immune responses to ovalbumin in mice. Vaccine 24 11 (2006) 1914-1920
52. Xie Y., Pan H.J., Sun H.X., and Li D. A promising balanced Th1 and Th2 directing immunological adjuvant, saponins from the root of Platycodon grandiflorum. Vaccine 26 31 (2008) 3937-3945
53. Sun H.X., and Zheng Q.F. Haemolytic activities and adjuvant effect of Gynostemma pentaphyllum saponins on the immune responses to ovalbumin in mice. Phytother Res 19 10 (2005) 895-900
54. Gupta R.K., and Siber G.R. Adjuvants for humans vaccines: current status, problems and future prospects. Vaccine 13 (1995) 1263-1266
55. Audibert F.M., and Lise L.D. Adjuvants: current status, clinical perspectives and future prospects. Immunol Today 14 (1993) 281-284
56. Sedlik C. Th1 and Th2 subsets of T lymphocytes: characteristics, physiological role and regulation. Bull Inst Pasteur 94 (1996) 173-200
57. Livingston P.O., Adluri S., Helling F., Yao T.J., Kensil C.R., Newman M.J., et al. Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 12 14 (1994) 1275-1280
58. Cher D.J., and Mosmann T.R. Two types of murine helper T-cell clones. II. Delayed-type hypersensitivity is mediated by Th1 clones. J Immunol 138 (1987) 3688-3694
59. Mosmann T.R., and Sad S. The expanding universe of T-cells subsets: Th1, Th2 and more. Immunol Today 17 (1996) 138-146
60. + Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor. J Exp Med 181 (1995) 1285-1292
61. Coffman R.L., Seymour B.W.P., Lebman D.A., Hiraki D.D., Christiansen J.A., Shrader B., et al. The role of helper T-cell products in mouse B-cell differentiation and isotype regulation. Immunol Rev 102 (1988) 5-28
62. + T cell responses: the alternative approaches. Annu Rev Immunol 15 (1997) 297-322
63. McKee A.S., Munks M.W., and Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27 5 (2007) 687-690
64. Finkelman F.D., Holmes J., Katona I.M., Urban Jr. J.F., Beckmann M.P., Park L.S., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 8 (1990) 303-333
65. Germann T., Bongartz M., Dlugonska H., Hess H., Schmitt E., Kolbe L., et al. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol 25 3 (1995) 823-829
66. Zheng W., and Flavell R.A. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89 4 (1997) 587-596
67. Szabo S.J., Kim S.T., Costa G.L., Zhang X., Fathman C.G., and Glimcher L.H. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100 6 (2000) 655-669
68. Chakir H., Wang H., Lefebvre D.E., Webb J., and Scott F.W. T-bet/GATA-3 ratio as a measure of the Th1/Th2 cytokine profile in mixed cell populations: predominant role of GATA-3. J Immunol Methods 278 1/2 (2003) 157-169
69. Kos F.J., and Engleman E.G. Immune regulation: a critical link between NK cells and CTLs. Immunol Today 17 (1996) 174-176
70. Medzhitov R., and Janeway Jr. C.A. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 9 (1997) 4-9
71. Boon T., Cerottini J.C., Van den Eynde B., van der Bruggen P., and Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12 (1994) 337-365
72. Moretta L., Bottino C., Cantoni C., Mingari M.C., and Moretta A. Human natural killer cell function and receptors. Curr Opin Pharmacol 1 (2001) 387-391
73. Rappuoli R. Bridging the knowledge gaps in vaccine design. Nat Biotechnol 25 (2007) 1361-1366
74. Orange J.S. Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol 8 (2008) 713-725
75. Zhang J., Sun R., Wei H.M., and Tian Z.G. Antitumor effects of recombinant human prolactin in human adenocarcinoma-bearing SCID mice with human NK cell xenograft. Int Immunopharmacol 5 (2005) 417-425